Immunic, Inc. is a late-stage biotechnology company developing novel oral therapies for neurologic and gastrointestinal diseases. The company's lead candidate, vidofludimus calcium, is in Phase 3 clinical trials for relapsing multiple sclerosis.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.